Search

Calling context profiling collects statistics separately for each calling context. Complete calling context profiles that faithfully represent overall program execution are important for a sound analysis of program behavior, which in turn is important for program understanding, reverse engineering, and workload characterization. Many existing calling context profilers for Java rely on sampling or on incomplete instrumentation techniques, yielding incomplete profiles; others rely on Java Virtual Machine (JVM) modifications or work only with one specific JVM, thus compromising portability. In this paper we present a new calling context profiler for Java that reconciles completeness of the collected profiles and full compatibility with any standard JVM. In order to reduce measurement perturbation, our profiler collects platform-independent dynamic metrics, such as the number of method invocations and the number of executed bytecodes. In contrast to prevailing calling context profilers, our tool is able to distinguish between multiple call sites in a method and supports selective profiling of (the dynamic extent of) certain methods. We have evaluate the overhead introduced by our profiler with standard Java and Scala benchmarks on a range of different JVMs.

A phase 1 trial of a candidate human immunodeficiency virus type 1 (HIV-I) vaccine was done in 25 healthy seronegative subjects. The antigen, env2-3 (SF2), was a nonglycosylated polypeptide representing the gp120 region of the env gene of the HIV-l(SF2) isolate. It was produced in genetically engineered yeast as a denatured molecule incapable of binding CD4. A synthetic lipophilic muramyl tripeptide (MTP-PE) was used as an adjuvant. Ten subjects received adjuvant alone and 15 received 50- or 25O-µg doses of env2-3 (SF2) administered intramuscularly in two immunization regimens. In general, adjuvant and vaccine were well tolerated. Antibody responses to both the homologous antigen, env2-3 (SF2), and antigens from other highly divergent HIV isolates were elicited in the majority of vaccine recipients. However, antibody titers were low, without neutralizing activity. In 9 of 11 subjects who received the complete vaccine immunization series, a significant specific T lymphocyte response was observed

Calling-context profiles and dynamic metrics at the bytecode level are important for profiling, workload characterization, program comprehension, and reverse engineering. Prevailing tools for collecting calling-context profiles or dynamic bytecode metrics often provide only incomplete information or suffer from limited compatibility with standard JVMs. However, completeness and accuracy of the profiles is essential for tasks such as workload characterization, and compatibility with standard JVMs is important to ensure that complex workloads can be executed. In this paper, we present the design and implementation of JP2, a new tool that profiles both the inter- and intra-procedural control flow of workloads on standard JVMs. JP2 produces calling-context profiles preserving callsite information, as well as execution statistics at the level of individual basic blocks of code. JP2 is complemented with scripts that compute various dynamic bytecode metrics from the profiles. As a case-study and tutorial on the use of JP2, we use it for crossprofiling for an embedded Java processor.

[Pradt (Dominique de Fourt de)], Comprend : Discours, Avec mode texte

A phase 1 trial of a candidate human immunodeficiency virus type 1 (HIV-I) vaccine was done in 25 healthy seronegative subjects. The antigen, env2-3 (SF2), was a nonglycosylated polypeptide representing the gp120 region of the env gene of the HIV-l(SF2) isolate. It was produced in genetically engineered yeast as a denatured molecule incapable of binding CD4. A synthetic lipophilic muramyl tripeptide (MTP-PE) was used as an adjuvant. Ten subjects received adjuvant alone and 15 received 50- or 25O-µg doses of env2-3 (SF2) administered intramuscularly in two immunization regimens. In general, adjuvant and vaccine were well tolerated. Antibody responses to both the homologous antigen, env2-3 (SF2), and antigens from other highly divergent HIV isolates were elicited in the majority of vaccine recipients. However, antibody titers were low, without neutralizing activity. In 9 of 11 subjects who received the complete vaccine immunization series, a significant specific T lymphocyte response was observed